Skip to main content
Quest Diagnostics

Changes in Newly Identified Cancer Among US Patients From Before COVID-19 Through the First Full Year of the Pandemic

Changes in Newly Identified Cancer Among US Patients From Before COVID-19 Through the First Full Year of the Pandemic

Authors: Kaufman HW, Chen Z, Niles JK, Fesko YA. 

Citation: JAMA Netw Open. 2021 Aug 2;4(8):e2125681. doi: 10.1001/jamanetworkopen.2021.25681.

Specialties: Infectious Disease, COVID-19, Oncology

Download key summary

Related content

Publication
Changes in ganglioside antibody positivity rates during the COVID-19 pandemic
Publication
Changes in Test Volumes During Coronavirus Disease 2019 (COVID-19): A Laboratory Stewardship Opportunity
Publication
Changes in the Number of US Patients With Newly Identified Cancer Before and During the Coronavirus Disease 2019 COVID 19 Pandemic
Publication
Assessing vulnerability to COVID 19 in high risk populations: the role of SARS CoV 2 spike targeted serology
Publication
Comparison of SARS-CoV-2 RT-PCR Ct values across multiple assays with different targets
Publication
SARS-CoV-2 Spike-Protein Targeted Serology Test Results and Their Association With Subsequent COVID-19-Related Outcomes

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.